Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca, GSK Will Close Plants In Europe

by Rick Mullin
December 1, 2008 | A version of this story appeared in Volume 86, Issue 48

AstraZeneca plans to close manufacturing sites in Porriño, Spain; Destelbergen, Belgium; and Umeå, Sweden, eliminating an estimated 1,400 jobs by 2013. Jobs may also be eliminated at facilities in Macclesfield, England, and Södertälje, Sweden. The plants involved primarily perform drug packaging and formulation. Meanwhile, the company says it is investing in its plant in Wuxi, China. "The moves are a continuation of AstraZeneca's program to improve the organization's productivity and efficiency," says David Smith, executive vice president of operations. In 2007, the company went through a reorganization that resulted in the elimination of 7,600 jobs. GlaxoSmithKline, meanwhile, plans to close its active pharmaceutical ingredients facility in Dartford, England, eliminating around 620 jobs. GSK says the site makes ingredients for a number of older products; it proposes to transfer production to contract manufacturing firms.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.